UNSPSC 51291511: Isocarboxazid

This classification denotes a monoamine oxidase inhibitor and antidepressant agent with the molecular formula C12H13N3O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 34237V843T, chemically known as 3-isoxazolecarboxylic acid, 5-methyl-, 2-(phenylmethyl)hydrazide but generally known as isocarboxazid, which bears US NIH Compound Identifier 3759. European Medicines Agency schedules Isocarboxazid in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08313MIG.

UNSPSC 51291511 Isocarboxazid is a Commodity code identifying a specific monoamine oxidase inhibitor antidepressant medication. State and local governments procure this pharmaceutical as part of broader community health, behavioral health, and emergency response programs, though recent solicitations under this code show substantial mismatch between the nominal product and the actual acquisitions being sought. The issuing bodies span county health departments, state health and human services agencies, and cooperative purchasing alliances serving multiple jurisdictions. These entities typically acquire pharmaceuticals through competitive bidding processes that bundle multiple drugs or therapeutic classes into single contracts to simplify vendor management and reduce administrative overhead.

Recent activity under the code reflects three distinct procurement models: Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually via competitive bidding with a July 26, 2023 response deadline and quarterly delivery to the Seminole County Community Health Building; the Texas Health and Human Services Commission posted RFI HHS0017013 in April 2026 to gather vendor capability information for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, seeking responses on April 3, 2026; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) administered by the Minnesota Department of Administration issued RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products serving state and local facilities across participating jurisdictions including Oregon, with proposals due March 26, 2026 and an effective date of July 1, 2026. The code shows activity concentrated in Florida, Texas, and Minnesota, with the cooperative purchasing model extending across multiple states. However, the recent opportunities tagged under this code involve naloxone (an opioid antagonist), general pharmaceutical procurement programs, and direct-to-manufacturer contracting models that diverge from isocarboxazid itself, suggesting tagging inconsistency in the underlying procurement records.